Our Goals
We are at a critical time point in Parkinson’s research. The number of people with Parkinson’s is expected to reach over 12 million by 2040.
Exciting advances mean a number of treatments with the potential to slow Parkinson’s are waiting to be tested. Now we crucially need a way to speed-up their assessment and provide the Parkinson’s community with answers. The current clinical trial process is unable to match the urgent pace required. To accelerate this process, there is a desperate need for smarter, faster, more cost-effective trials. EJS ACT-PD’s goal is to address this challenge, and fast-track trials in to treatments for Parkinson’s.
We want to transform and speed-up the testing of treatments that can slow or stop Parkinson’s
See our answers to the questions below:
Answer:
The way clinical trials are currently set up, treatments are tested one at a time and the trial process is repeated as it passes through the clinical phases. This makes it a very lengthy and inefficient process. We urgently need faster, smarter trials that can speed-up this process.
Answer:
Our plan is to set up a multi-arm trial that can assess several treatments simultaneously. We will analyse treatments regularly to see if they appear to be effective. Those that seem effective will be continued, and those that don’t will be replaced with new possible treatment options, without any delay being incurred.
Answer:
We’ve assembled multiple expert groups to focus on the different decisions required to produce the trial. Most importantly, people with Parkinson’s and their caregivers are involved in all of the decision-making processes, so that we remain focused on patient needs.